What is the market price of one tube of Enfortumab?

Enfortumab/Enfortumab is mainly used for the treatment of advanced or metastatic urothelial cancer (mUC; bladder cancer), especially in patients who have failed to respond to standard chemotherapy and immune checkpoint inhibitors. Its mechanism of action is based on antibody-drug conjugate (ADC) technology. The monoclonal antibody targets the nectin-4 protein and couples the cytotoxic microtubule inhibitor to the antibody, which directly enters cancer cells and releases toxic molecules, thereby selectively killing tumor cells while reducing damage to normal cells. This targeted therapy significantly improved the overall response rate of advanced patients and showed a controllable safety profile in overseas clinical trials.

Clinically, veentuzumab is usually administered via intravenous infusion, with a course of treatment every 21 days, and the dose is adjusted according to the patient's weight. Its application is not only suitable for patients with chemotherapy resistance, but also provides a new treatment approach for patients after immunotherapy has progressed, significantly expanding the range of treatment options for urothelial cancer. Practice in many overseas countries has shown that venetuzumab can achieve a certain proportion of tumor remission in combination or monotherapy, bringing considerable survival benefits to advanced patients.

Regarding the market price, the domestic patent drug Vientuzumab for injection has been launched, but due to the short time, the specific price information has not been fully announced. In overseas markets, the price of the European version of veentuzumab is about more than RMB 7,000 per box in the 20 mg format, while the price in the 30 mg format may be more than RMB 10,000 per box. Prices may fluctuate due to exchange rates and regional policies. There are currently no generic drugs on the market, so patients can only choose original drugs, which have relatively high market prices. As the domestic market further improves and medical insurance policies are implemented, prices may be adjusted in the future. Especially after medical insurance negotiations or patient assistance projects, the out-of-pocket burden is expected to be significantly reduced.

Reference: https://www.padcev.com/